Zepatier for 8 weeks safe, effective for HCV genotypes 1b, 4
Click Here to Manage Email Alerts
PARIS — In this exclusive interview from the International Liver Congress 2018, Christophe Hezode, MD, discusses positive study results from two presentations on 8-week courses of Zepatier for hepatitis C in different patient populations.
“It’s very interesting to note that in the new EASL guidelines, the recommendation is to treat these patients for 8 weeks with grazoprevir and elbasvir, so it’s validated in the new EASL guidelines,” Hezode, of Hopital Henri Mondor, Paris, France, told Healio Gastroenterology and Liver Disease.
The first study, presented by Armand Abergel, MD, PhD, from Chu Estaing in France, showed a sustained virologic response rate of 98% among treatment-naive patients with HCV genotype 1b and minimal fibrosis who received Zepatier (elbasvir/grazoprevir, Merck) for 8 weeks.
In the second study, presented by Tarik Asselah, MD, from the Hôpital Beaujon in France, preliminary results suggest that 8 weeks of elbasvir/grazoprevir may be effective, safe and well-tolerated in treatment-naive patients with HCV genotype 4 with minimal fibrosis.
For more information:
Abergel A, et al. LBP-010. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.
Asselah T, et al. GS-006. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.
Disclosure: Hezode reports financial relationships with AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck.